Europeanhhm

Px HealthCare Introduces Groundbreaking Real-World Evidence Study Utilizing OWise Breast Cancer Patient Support App

Friday, December 08, 2023

Px HealthCare has recently unveiled a groundbreaking Real World Evidence (RWE) study during the San Antonio Breast Cancer Symposium (SABCS), in collaboration with AstraZeneca UK. The study, known as RELATE-2, is a nationwide initiative that invites breast cancer patients in the UK, prescribed with trastuzumab deruxtecan (TDX-d, Enhertu) or olaparib (Lynparza), to participate through the OWise cancer patient support app. To cater to these patients, two specialized versions of the OWise app have been developed, aligning with the licensed indications for each treatment.

An innovative and patient-centered approach, the RELATE-2 study seeks to evaluate the experiences of individuals undergoing treatment with TDX-d or olaparib while utilizing the OWise treatment-specific modules. This initiative represents a novel method for conducting Real World Evidence research, placing a strong emphasis on patient perspectives.

The OWise breast cancer app, freely available to patients prescribed with TDX-d or olaparib, offers personalized support, aiming to empower individuals and provide valuable insights that have the potential to reshape patient care. Notably, the app facilitates direct patient consent and participation in clinical research, streamlining the process and fostering increased engagement in research efforts. The collaborative efforts of Px HealthCare and AstraZeneca UK reflect a commitment to leveraging digital health solutions to enhance patient experiences and generate real-world evidence for continuous improvement in cancer care.

Source: prnewswire.com

Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare Innovation & Transformation SummitHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement Summit 2024